Venturi Wealth Management LLC Has $78,000 Holdings in Agilent Technologies, Inc. (NYSE:A)

Venturi Wealth Management LLC raised its stake in shares of Agilent Technologies, Inc. (NYSE:A) by 95.9% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 523 shares of the medical research company’s stock after purchasing an additional 256 shares during the period. Venturi Wealth Management LLC’s holdings in Agilent Technologies were worth $78,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in shares of Agilent Technologies by 18.2% during the 1st quarter. Vanguard Group Inc. now owns 29,884,345 shares of the medical research company’s stock worth $4,348,471,000 after buying an additional 4,605,228 shares in the last quarter. Massachusetts Financial Services Co. MA increased its position in shares of Agilent Technologies by 5.7% during the second quarter. Massachusetts Financial Services Co. MA now owns 15,064,660 shares of the medical research company’s stock valued at $1,952,832,000 after acquiring an additional 809,149 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Agilent Technologies by 13.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 8,542,054 shares of the medical research company’s stock worth $1,242,956,000 after acquiring an additional 1,042,926 shares during the period. Van ECK Associates Corp boosted its position in Agilent Technologies by 6.6% in the third quarter. Van ECK Associates Corp now owns 2,976,905 shares of the medical research company’s stock worth $442,011,000 after purchasing an additional 183,716 shares during the last quarter. Finally, Impax Asset Management Group plc grew its stake in Agilent Technologies by 8.2% in the 3rd quarter. Impax Asset Management Group plc now owns 2,667,616 shares of the medical research company’s stock valued at $396,088,000 after purchasing an additional 203,234 shares during the period. 87.42% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. UBS Group increased their price target on shares of Agilent Technologies from $141.00 to $150.00 and gave the company a “neutral” rating in a research report on Thursday, August 22nd. Stifel Nicolaus reissued a “buy” rating and set a $151.00 target price on shares of Agilent Technologies in a research report on Monday, August 26th. Wells Fargo & Company began coverage on shares of Agilent Technologies in a report on Tuesday, August 27th. They issued an “overweight” rating and a $157.00 price target on the stock. Barclays increased their price objective on Agilent Technologies from $135.00 to $145.00 and gave the company an “underweight” rating in a report on Tuesday, October 15th. Finally, Evercore ISI boosted their target price on Agilent Technologies from $135.00 to $145.00 and gave the company an “in-line” rating in a research note on Tuesday, October 1st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, Agilent Technologies has a consensus rating of “Moderate Buy” and a consensus price target of $144.36.

Agilent Technologies Trading Down 3.0 %

Shares of Agilent Technologies stock opened at $130.22 on Friday. Agilent Technologies, Inc. has a fifty-two week low of $111.33 and a fifty-two week high of $155.35. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.37 and a current ratio of 1.78. The company has a market capitalization of $37.42 billion, a P/E ratio of 27.02, a P/E/G ratio of 5.88 and a beta of 1.07. The company has a fifty day moving average of $139.09 and a 200 day moving average of $138.14.

Agilent Technologies (NYSE:A) last released its quarterly earnings data on Wednesday, August 21st. The medical research company reported $1.32 EPS for the quarter, beating the consensus estimate of $1.26 by $0.06. Agilent Technologies had a net margin of 21.75% and a return on equity of 25.26%. The business had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.56 billion. During the same quarter in the prior year, the firm earned $1.43 EPS. The business’s revenue was down 5.6% on a year-over-year basis. On average, sell-side analysts anticipate that Agilent Technologies, Inc. will post 5.24 earnings per share for the current fiscal year.

Agilent Technologies Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, October 23rd. Shareholders of record on Tuesday, October 1st were given a $0.236 dividend. The ex-dividend date was Tuesday, October 1st. This represents a $0.94 annualized dividend and a yield of 0.72%. Agilent Technologies’s dividend payout ratio (DPR) is 19.50%.

Insider Activity at Agilent Technologies

In other Agilent Technologies news, SVP Dominique Grau sold 9,990 shares of the business’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $145.00, for a total value of $1,448,550.00. Following the completion of the transaction, the senior vice president now directly owns 40,011 shares in the company, valued at approximately $5,801,595. The trade was a 19.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Padraig Mcdonnell sold 1,958 shares of the stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $145.00, for a total value of $283,910.00. Following the sale, the chief executive officer now owns 24,118 shares of the company’s stock, valued at approximately $3,497,110. This represents a 7.51 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 11,995 shares of company stock worth $1,739,510. Company insiders own 0.33% of the company’s stock.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.